John Shea of the San Francisco Chronicle asks whether Jeff Kent gets extra credit, if you will, when he’s up for the Hall of Fame next year due to the fact that he was an outspoken critic of baseball’s lack of drug testing:
Perhaps more than any other ballplayer, Kent lobbied for testing when it wasn’t trendy, when the union and much of its membership fought against it. In a clubhouse in which Greg Anderson once had free rein as a drug runner for Bonds and other Giants, Kent often stood at his locker and called for Major League Baseball and the union to iron out a legitimate steroids policy.
Shea details more of the ways in which Kent demonstrated his disapproval of PEDs in baseball.
Which is well and good, but I also wonder why, given the lessons of recent history, any athlete is to be take at his word with respect to PEDs, either positively or negatively.
Rangers’ bullpen candidate Tanner Scheppers left Friday’s Cactus League game with pain in his “lower half,” according to reports by Evan Grant of the Dallas Morning News. The specifics of the right-hander’s injury have yet to be determined, but he was accompanied by the athletic trainer when he exited the game and is scheduled to undergo an MRI on Saturday.
Scheppers, 30, has a long history of elbow and knee injuries. He missed all but 8 2/3 innings of the 2016 season after undergoing a procedure to repair torn articular cartilage in his left knee. While he appeared healthy enough through his first seven appearances this spring, he failed to impress with three runs, five walks and six strikeouts over 7 2/3 innings with the club.
Should Scheppers find himself on the disabled list for another lengthy stay, MLB.com’s T.R. Sullivan speculates that his absence could clear some room in the bullpen for Rule 5 draft pick and fellow righty Mike Hauschild. Hauschild, 27, has dealt seven runs, five walks and 15 strikeouts through 17 1/3 innings in camp.
Yahoo Sports’ Jeff Passan reports that third baseman Jose Ramirez is finalizing a four-year extension with the Indians. The deal is said to be worth north of $30 million, and may crest $50 million if all options are exercised. While the extension won’t take effect until the 2018 season, it guarantees Ramirez a $26 million sum with two options worth $11 and $13 million and will give the Indians control of the infielder through the 2023 season.
Ramirez, 24, is entering his fifth season in the Indians’ organization. He posted career-high numbers during his first full season in the majors, slashing .312/.363/.461 with 11 home runs, 22 stolen bases and 4.8 fWAR in 2016. He’s projected to have a strong follow-up season at the plate and will likely see some time at second base as Jason Kipnis works his way back from a shoulder injury.
Although 2016 only showcased the beginning of Ramirez’s success with the club, FanRag Sports’ Jon Heyman says it’s a standard move for Cleveland to “sign their stars early,” and indicates that Ramirez was rumored to want the deal. Jeff Todd of MLB Trade Rumors adds that the extension will keep Ramirez under club control through three arbitration-eligible years and one year of potential free agency.